Merck/Schering Zetia Effects On Triglycerides, HDL-C Questioned In Review
Executive Summary
FDA and Merck/Schering-Plough reached a middle ground on Zetia's indication, allowing the "small" effects on triglycerides and HDL-cholesterol to be described in the clinical studies section of labeling but not in the indication, NDA review documents show
You may also be interested in...
Schering/Merck Zetia Clears FDA; Price Favors Combo With Low-Dose Zocor
Merck and Schering-Plough are pricing Zetia so that combination use with Zocor 10 mg is attractive compared to high-dose Zocor monotherapy
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials